Critical pathways leading to obliterative bronchiolitis in lung allografts

Current Opinion in Organ Transplantation

Volumn 11, Issue 5, 2006, Pages 483-489

  Babu, Ashok N ^a   Nicolls, Mark R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Bronchiolitis; Fibrosis; Lung; Obliterans; Obliterative; Transplant

Indexed keywords

COLLAGEN; DISCOIDIN DOMAIN RECEPTOR; GROWTH FACTOR; LECTIN RECEPTOR; MATRIX METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

AIRWAY; ALLOIMMUNITY; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; BRONCHIOLITIS OBLITERANS; BRONCHUS MUCOSA; CELL ACTIVATION; CELL PROLIFERATION; CELL REGENERATION; CHRONOLOGY; CLINICAL PATHWAY; CLINICAL RESEARCH; COLLAGEN SYNTHESIS; DATA ANALYSIS; DISEASE COURSE; EXTRACELLULAR MATRIX; FIBROBLAST; GASTROESOPHAGEAL REFLUX; HUMAN; INNATE IMMUNITY; LUNG FIBROSIS; LUNG INJURY; LUNG TRANSPLANTATION; MEDICAL LITERATURE; MESENCHYME; MOLECULAR RECOGNITION; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PNEUMONIA; PROTEIN SYNTHESIS; RESPIRATORY EPITHELIUM; REVIEW; RISK FACTOR; TARGET CELL; TREATMENT PLANNING;

EID: 33748803896     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/01.mot.0000244650.00717.9c     Document Type: Review

References (45)

1. Wilkes DS, Egan TM, Reynolds HY. Lung transplantation: opportunities for research and clinical advancement. Am J Respir Crit Care Med 2005; 172:944-955. Summary of a workshop specifying currently relevant deficiencies in lung transplantation and steps to address these issues: (1) organ shortage; (2) preservation; (3) acute graft failure; (4) infections; and (5) BOS.
2. Hertz MI, Taylor DO, Trulock EP, et al. The registry of the International Society for Heart and Lung Transplantation: 19th official report. J Heart Lung Transplant 2002; 21:950-970.
3. Trulock EP. Lung transplantation. Am J Respir Crit Care Med 1997; 155:789-818.
4. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004; 4:583-594.
5. Murakawa T, Kerklo MM, Zamora MR, et al. Simultaneous LFA-1 and CD40 ligand antagonism prevents airway remodeling in orthotopic airway transplantation: implications for the role of respiratory epithelium as a modulator of fibrosis. J Immunol 2005; 174:3869-3879. A scientific paper utilizing an orthotopic tracheal transplant model to study alloimmune airway remodeling. A large degree of epithelial chimerism was found to be highly associated with fibrosis in this model.
6. Uhal BD, Joshi I, True AL, et al. Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. Am J Physiol 1995; 269:L819-L828.
7. Lee JM, Dedhar S, Kalluri R, et al. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172:973-981. A summary of proceedings at the EMT (Epithelial Mesenchymal Transition) International Association Meeting, 2002, in Vancouver regarding recent developments in signaling pathway activation of EMT, and its role in cancer and fibrosis.
8. Schmidt M, Sun G, Stacey MA, et al. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 2003; 171:380-389.
9. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112:1776-1784.
10. Ward C, Forrest IA, Murphy DM, et al. Phenotype of airway epithelial cells suggests epithelial to mesenchymal cell transition in clinically stable lung transplant recipients. Thorax 2005; 60:865-871. This scientific paper demonstrates airway epithelium staining positive for fibroblast specific protein 1 in clinically stable human lung transplant patients, suggesting a role for EMT in the pathogenesis of BOS.
11. Iwano M, Plieth D, Danoff TM, et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110:341-350.
12. Willis BC, Liebler JM, Luby-Phelps K, et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005; 166:1321-1332. Rat alveolar epithelial cells exposed to TGF-β1 in vitro began to express fibroblastic markers such as alpha smooth muscle actin, collagen, vimentin, and desmin. IPF lung tissues specimens demonstrated epithelial cells that stained positive for epithelial markers as well as alpha smooth muscle actin.
13. Chilosi M, Poletti V, Zamo A, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003; 162:1495-1502.
14. Douglas IS, Diaz del Valle F, Winn RA, et al. Beta-catenin in the fibroproliferative response to acute lung injury. Am J Respir Cell Mol Biol 2006; 34:274-285. A scientific paper that demonstrates the activation of beta-catenin pathways after acute lung injury in a murine model.
15. Postlethwaite AE, Keski-Oja J, Moses HL, et al. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta. J Exp Med 1987; 165:251-256.
16. El-Gamel A, Sim E, Hasleton P, et al. Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant 1999; 18:828-837.
17. Mirkovic S, Seymour AM, Fenning A, et al. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol 2002; 135:961-968.
18. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999; 291:367-373.
19. Raghu G, Johnson WC, Lockhart D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999; 159:1061-1069.
20. McKane BW, Fernandez F, Narayanan K, et al. Pirfenidone inhibits obliterative airway disease in a murine heterotopic tracheal transplant model. Transplantation 2004; 77:664-669.
21. Zhou H, Latham CW, Zander DS, et al. Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts. J Heart Lung Transplant 2005; 24:1577-1585. A scientific paper utilizing a murine heterotopic tracheal transplant model that demonstrated protection against luminal fibrosis and epithelial loss in allografts treated with pirfenidone from day -1. Pirfenidone-treated animals had less local TGF-β expression.
22. Liu H, Drew P, Gaugler AC, et al. Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway. Am J Transplant 2005; 5:1256-1263. A scientific paper utilizing a rat single lung transplant model to demonstrate that pirfenidone largely abrogated the fibrosis in rejecting allografts that translated to decreased peak airway pressures. Pirfenidone therapy also abrogated the increase in arginase protein expression.
23. Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell 1986; 46:155-169.
24. Hertz MI, Henke CA, Nakhleh RE, et al. Obliterative bronchiolitis after lung transplantation: a fibroproliferative disorder associated with platelet-derived growth factor. Proc Natl Acad Sci U S A 1992; 89:10385-10389.
25. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004; 9:271-281.
26. Kallio EA, Koskinen PK, Aavik E, et al. Role of platelet-derived growth factor in obliterative bronchiolitis (chronic rejection) in the rat. Am J Respir Crit Care Med 1999; 160:1324-1332.
27. Krebs R, Tikkanen JM, Nykanen AI, et al. Dual role of vascular endothelial growth factor in experimental obliterative bronchiolitis. Am J Respir Crit Care Med 2005; 171:1421-1429. A scientific paper utilizing a rat heterotopic tracheal transplant model demonstrated that the administration of imatinib (a non-selective RTK inhibitor that affects PDGF, bcr-abl, and c-kit) along with VEGF overexpression resulted in the prevention of luminal fibrosis and complete epithelial preservation.
28. Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006; 173:769-776. A scientific paper utilizing a bleomycin acute lung injury rat model to define the inflammatory versus fibroproliferative phases of acute lung injury. To answer this question, the authors recently published a study looking at the effects of PDGF antagonism with respect to the inflammatory and fibroproliferative phases after bleomycin-induced acute lung injury in rats. Immunosuppressants were ineffective when used as late as day 10 after injury. Imatinib RTK inhibition appeared to decrease profibrotic gene expression at day 21 to normal levels when administered at day 1 or day 10, suggesting that it is effective even once fibroproliferation has begun.
29. Sivakumar B, Harry LE, Paleolog EM. Modulating angiogenesis: more vs less. JAMA 2004; 292:972-977.
30. Belperio JA, Keane MP, Burdick MD, et al. Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest 2005; 115:1150-1162. A scientific paper utilizing a murine HTT model to demonstrated that angiogenesis in this model was CXCR2 dependent, and CXCR2 blockade prevented angiogenesis and fibrosis
31. O'Connor CM, FitzGerald MX. Matrix metalloproteases and lung disease. Thorax 1994; 49:602-609.
32. Taghavi S, Krenn K, Jaksch P, et al. Broncho-alveolar lavage matrix metalloproteases as a sensitive measure of bronchiolitis obliterans. Am J Transplant 2005; 5:1548-1552.
33. Hubner RH, Meffert S, Mundt U, et al. Matrix metalloproteinase-9 in bronchiolitis obliterans syndrome after lung transplantation. Eur Respir J 2005; 25:494-501. A scientific study that measured MMP9 and TIMP-1 in BAL fluid from patients with and without BOS. The MMP-9/TIMP-1 ratio was significantly increased in the BOS group and neutrophils were the primary source of MMP9.
34. Fernandez FG, Campbell LG, Liu W, et al. Inhibition of obliterative airway disease development in murine tracheal allografts by matrix metalloproteinase-9 deficiency. Am J Transplant 2005; 5:671-683. A scientific paper utilizing a murine heterotopic tracheal transplant model to demonstrate that MMP9 knockout recipients of tracheal allografts had significantly decreased luminal occlusion.
35. Chen P, Farivar AS, Mulligan MS, et al. Tissue inhibitor of metalloproteinase-1 deficiency abrogates obliterative airway disease after heterotopic tracheal transplantation. Am J Respir Cell Mol Biol 2006; 34:464-472. A scientific paper utilizing a murine heterotopic tracheal transplant model to demonstrate that when recipients or donors are deficient in TIMP-1, there is increased re-epithelialization and decreased luminal obliteration.
36. Vogel WF, Abdulhussein R, Ford CE. Sensing extracellular matrix: an update on discoidin domain receptor function. Cell Signal 2006; 18:1108-1116.
37. Matsuyama W, Mitsuyama H, Watanabe M, et al. Involvement of discoidin domain receptor 1 in the deterioration of pulmonary sarcoidosis. Am J Respir Cell Mol Biol 2005; 33:565-573. A scientific paper that demonstrated that BAL fluid macrophages from patients with deteriorating pulmonary sarcoidosis selectively express the DDR1 isoform DDR1b, and when exposed to collagen express monocyte chemoattractant protein 1, IL-8, macrophage inflammatory protein 1 alpha, and MMP9.
38. Matsuyama W, Watanabe M, Shirahama Y, et al. Discoidin domain receptor 1 contributes to the survival of lung fibroblast in idiopathic pulmonary fibrosis. Am J Pathol 2006; 168:866-877.
39. Matsuyama W, Watanabe M, Shirahama Y, et al. Suppression of discoidin domain receptor 1 by RNA interference attenuates lung inflammation. J Immunol 2006; 176:1928-1936.
40. Raghu G. The role of gastroesophageal reflux in idiopathic pulmonary fibrosis. Am J Med 2003; 115 (Suppl 3A):60S-64S.
41. Vincent D, Cohen-Jonathan AM, Leport J, et al. Gastro-oesophageal reflux prevalence and relationship with bronchial reactivity in asthma. Eur Respir J 1997; 10:2255-2259.
42. D'Ovidio F, Mura M, Tsang M, et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg 2005; 129:1144-1152. A clinical paper that found that 17% of lung allograft recipients had elevated bilirubin levels in BAL fluid and this was a marker for the future development of BOS.
43. Young LR, Hadjiliadis D, Davis RD, et al. Lung transplantation exacerbates gastroesophageal reflux disease. Chest 2003; 124:1689-1693.
44. Davis RD Jr, Lau CL, Eubanks S, et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 2003; 125:533-542.
45. Cantu E, Appel JZ III, Hartwig MG, et al. J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg 2004; 78:1142-1151.